PERTIMBANGAN PEMAKAIAN ANTIBIOTIK PADA SEPSIS NEONATAL



Dr. Ariantana, Sp.A RSIA Limijati 29-30 Mei 2021

INTRODUCTION

- ✓ Neonatal sepsis is a global challenge causing high morbidity and mortality among newborns
- ✓ Late-onset sepsis (LOS) in preterm infants is a leading cause of mortality and morbidity
- ✓ Timely recognition and initiation of antibiotics are important factors for improved outcomes
- Antimicrobial therapy in most developing countries are mainly empirical due to a relative lack of appropriate laboratory facilities for culture and sensitivity of bacteria in several health facilities
- ✓ Antimicrobial resistance become a major concern

Alebachew Woldu M., Pediatr Ther. 2014;04 (04).

EPIDEMIOLOGY

The incidence of neonatal sepsis in developing countries is approximately 10 cases/ 1000 live births and as high as 13 - 27 per 1000 for premature live births. A report from the largest hospital in Indonesia found an incidence of 35%.

The incidence rates for LOS in preterm infants vary between 20 and 38% in the first 120 days of life, and mortality rates range from 13 to 19%.

LOS 10x>EOS


El Manouni El Hassani S, Berkhout DJC, Niemarkt HJ, Mann S, De Boode WP, Cossey V, et al. Risk factors for late-onset sepsis in preterm infants: A multicenter case-control study. Neonatology. 2019;116(1):42–51.

FAKTOR YANG BERKONTRIBUSI

Factors contributing to increased risk of LONS in premature infants:

(Adapted from: Neoreviews 2012;13;e94.)





Preterm neonates are at higher risk for sepsis/infection than term neonates.

The increased susceptibility for infections seen in preterm neonates is mainly due to :

Deficient immune system, mainly due to decreased IgG antibodies and incompetent opsonization and complement activation.

Comprised innate immune system, caused primarily by the immature epithelial barrier.

The increased need for invasive devices (vascular access, endotracheal tube, feeding tubes and urinary tract catheters) due to associated severe illnesses.

TANTANGAN

CHALLENGES IN THE DIAGNOSIS OF NEONATAL SEPSIS

- ✓ The clinical diagnosis of infection in a neonate is unreliable and that excessive.
- ✓ Many early signs of infection in neonates are nonspecific and may also be simply associated with prematurity or the transition to extrauterine life
- ✓ Unnecessary empiric antimicrobial therapy for the treatment of suspected sepsis can promote antimicrobial resistance
- ✓ There is a heightened need for an accurate and sensitive diagnostic tool to confirm the diagnosis of neonatal sepsis

Iroh Tam PY, Bendel CM. Diagnostics for neonatal sepsis: Current approaches and future directions. Pediatr Res [Internet]. 2017;82(4):574–83. Available from: http://dx.doi.org/10.1038/pr.2017.134

DEFINISI

DEFINITION

The incidence of LOS has increased in parallel with the improved survival of premature infants, especially in those with very low birth weight (VLBW), indicating the role of hospitalisation and life-sustaining medical devices in the pathogenesis of neonatal LOS.

Neonatal sepsis categorized

| Early Onset | Late Onset |
|--|---|
| At or before 72 hours of life (<+/- 7 days) | After 72 hours of life (> +/- 7 days) |
| Eos reflects transplacental or, more frequently, ascending infections from the maternal genital tract | Associated with the postnatal nosocomial or community environment, with the peak incidence reported to be between the 10th and 22nd day of life |

TANDA INFEKSI

- ✓ Community vs hospital associated infections (HAIs)
- ✓ HAIs: CRBSI, HAP, VAP, CAUTI, SSI
- ✓ Multisystemic or focal (such as UTI, abdominal, meningitis, pneumonia, omphalitis, osteomyelitis, septic arthritis, etc)

HAI's di NICU

| | Africa | Southeast Asia | South Asia | Latin America, Caribbean | Middle east, central Asia | All developing regions |
|----------------------------------|-------------|----------------|--------------|--------------------------|---------------------------|------------------------|
| All gram positives | 606 (38-8%) | 926 (41-1%) | 1857 (31-0%) | 533 (41.7%) | 148 (37-9%) | 4070 (35-5%) |
| S aureus | 224 (14-3%) | 181 (8.0%) | 1206 (20-2%) | 178 (13.9%) | 86 (22.1%) | 1875 (16-3%) |
| Coagulase-negative staphylococci | 122 (7.8%) | 621 (27-5%) | 356 (5.9%) | 246 (19-2%) | 46 (11-8%) | 1391 (12-1%) |
| Group B streptococci | 133 (8-5%) | 43 (1.9%) | 31 (0.5%) | 53 (4-1%) | 4(10%) | 264 (2.3%) |
| Other streptococci | 45 (2.9%) | 14 (0-6) | 101 (1.7%) | 16 (1.3%) | 2 (0.5%) | 178 (16%) |
| Group D streptococci/enterococci | 27 (1.7%) | 1 (0.04%) | 132 (2.2%) | 22 (1.7%) | 9 (2.3%) | 191 (1.7%) |
| S pneumoniae | 35 (2.2%) | 3 (0.1%) | 15 (0-3%) | 4 (0-5%) | 1 (0-3%) | 58 (0.5%) |
| Group A streptococci | 3 (0.2%) | 3 (0.1%) | 6 (0.1%) | 8 (0.9%) | | 20 (0-2%) |
| Listeria spp | 7 (0-4%) | | | 6 (0-5%) | | 13 (0.1%) |
| Other gram positives | 10 (0.6%) | 60 (2.7%) | 10 (0.2%) | | | 80 (0-7%) |
| All gram negatives | 938 (60-0%) | 1262 (56-0%) | 3793 (63-4%) | 709 (55-4%) | 239 (61-3%) | 6941 (60-5%) |
| Klebsiella spp | 441 (28-2%) | 435 (19-3%) | 1450 (24-2%) | 204 (15.9%) | 88 (22.6%) | 2618 (22-8%) |
| E coli | 155 (9.9%) | 108 (4-8%) | 984 (16-4%) | 116 (9-1%) | 40 (10-3%) | 1403 (12-2%) |
| Pseudomonas spp | 51 (3.3%) | 158 (7.0%) | 576 (9-6%) | 92 (7.2%) | 27 (6.9%) | 904 (7.9%) |
| Acinetobacter spp | 4 (0.3%) | 290 (12.9%) | 251 (4.2%) | 26 (2.0%) | 5 (1.3%) | 576 (5-0%) |
| Citrobacter spp | 42 (2.7%) | | 54 (0.9%) | 11 (1.3%) | 3 (0.8%) | 110 (10%) |
| Enterobacter spp | 66 (4-2%) | 105 (4.7%) | 287 (4-8%) | 153 (12-0%) | 24 (6-2%) | 635 (5.5%) |
| Salmonella spp | 24 (1.5%) | 2 (0.1%) | 51 (0.9%) | 14 (1.6%) | 5 (1.3%) | 96 (0.9%) |
| Proteus spp | 12 (0.8%) | 3 (0.1%) | 47 (0.8%) | 26 (3.0%) | 3 (0.8%) | 91 (0-8%) |
| Serratia spp | | | 1 (0.02%) | 14 (1.6%) | 13 (3.3%) | 28 (0-3%) |
| N meningi tidis | 2 (0-1%) | | | 2 (0-2%) | 3 (0.8%) | 7 (0-1%) |
| Haemophilus spp | 3 (0.2%) | | | 7 (0-8%) | 2 (0.5%) | 12 (0.1%) |
| Flavo bacterium meningosepticum | | 8 (0.4%) | 2 (0.03%) | | | 10 (0.1%) |
| Other gram negatives | 138 (8-8%) | 153 (6-8%) | 90 (1.5%) | 44 (3.4%) | 26 (6-7%) | 451 (3.9%) |
| Candida spp | 5 (0.3%) | 33 (1.5%) | 170 (2.8%) | 34 (2.7%) | | 242 (2.1%) |
| Other pathogens | 14 (0.9%) | 34(1.5%) | 164 (2.7%) | 3 (0-6%) | 3 (0-8%) | 218 (1.9%) |
| Total | 1563 | 2255 | 5984 | 1279 | | 11471 |

Group B Streptoccus (GBS)

How about GBS? Is it real in Indonesia?

GBS colonization was found in **53 (30%) pregnant women** Serotype II was the most common serotype (30%) followed by serotype III (23%), Ia and IV (13% each), VI (8%), Ib and V (6% each), and one non-typeable strain

| Antimicrobial agent | Susceptible, n (%) | Intermediate, n (%) | Resistance, n (%) |
|---------------------|-----------------------|------------------------|----------------------|
| Erythromycin | 43 (81) | 0 | 10 (19) |
| Clindamycin | 41 (77) | 1 (2) | 11 (21) |
| Vancomycin | 53 (100) | 0 | 0 |
| Penicillin | 53 (100) | 0 | 0 |
| Tetracycline | 6 (11) | 0 | 47 (89) |
| Ampicillin | 53 (100) | 0 | 0 |
| Levofloxacin | 50 (94) | 0 | 3 (6) |
| Cefotaxime | 53 (100) | 0 | 0 |
| Daptomycin | 53 (100) | 0 | 0 |
| Linezolid | 53 (100) | 0 | 0 |


BAKTERIA PENYEBAB

High light bacteria

- Cons:
 - Staphylococcal epidermidis, S. hominis
 - Source: hands, lipid, central access
- Enterobacteriaceae:
 - K. pneumoniae, E.coli
 - Source: BF, FM,
- Non fermenter:
 - Acinetobacter baumanii: persist in the hospital environment and has the ability to develop resistance to a majority of antimicrobials
 - Pseudomonas
 - Source: environment, water

FAKTOR LAIN LATE ONSET SEPSIS NEONATAL

Common non-bacterial agents associated with neonatal sepsis include:



Armsby C. Official reprint from UpToDate. www.uptodate.com ©2017 UpToDate ® Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants. 2017;1–23.

PEMERIKSAAN LABORATORIUM

INVESTIGATIONS FOR LATE ONSET NEONATAL SEPSIS

In the case of suspected LONS the infant should have the following investigations:

| Blood cultures | Urine microbiology |
|----------------------|--|
| FBC | CXR +/- AXR |
| CRP | LP |
| Respiratory secretic | ons if ventilated or respiratory signs |
| Thorough multi-sys | tem examination |



PEMERIKSAAN PUNKSI LUMBAL

Lumbal Puncture indications & contraindications

| INDICATIONS | CONTRAINDICATIONS |
|--------------------------------------|--|
| Clinical signs of meningitis | Abnormal clotting |
| Signs of systemic bacteraemia | Thrombocytopenia |
| Positive blood culture (except CoNS) | Clinically well |
| CRP > 30 | Definite focus of infection outside the CNS e.g. NEC |

PENDEKATAN DIAGNOSA LATE ONSET SEPSIS NEONATAL

- ✓ The gold standard the growth of pathogenic microorganisms in body fluids (blood, urine, cerebrospinal fluid, pleural fluid, peritoneal fluid, joint fluid) that are expected to be sterile.
- ✓ This 'gold standard' testing method is time-consuming and may produce false positive results as well as false negative results
- ✓ Timely and accurate diagnosis of LOS is of utmost importance
- ✓ The total number of neutrophils, immature to total neutrophil ratio and CRP holds promise
 to enable a fast and accurate diagnosis of LOS
- ✓ Sequential detection of CRP may help to rule out microbial infections in a timely manner, facilitating an early cessation of antibiotic treatment

MARKER INFLAMASI LAINNYA

| C-reactive protein (CRP) | CRP is increased in inflammatory conditions, including sepsis CRP → repeat after 24h may be helpful in determining whether infection is a significant likelihood. If the CRP level remains persistently normal (<1 mg/dL [10 mg/L]), neonatal bacterial sepsis is unlikely |
|-------------------------------|--|
| High Sensitivity CRP (hs-CRP) | High Sensitivity CRP (hs-CRP) > sensitive than conventional CRP The normal lower value of conventional CRP is accepted as 1 mg/dL, this value is 1 mg/L for hs-CRP high hs-CRP values were reported to have a significant increase in hs-CRP compared to non-infected newborns No risk of infection when the hs-CRP value is detected as <0.5 mg/L Low infection risk when the value is between 0.5–1 mg/L Moderate infection risk when between 1–3 mg/L High risk of infection at values >3 mg/L |
| Procalcitonin | The PCT level rises rapidly 2-4 hours after exposure to bacterial endotoxin, reaches a peak in 6-8 hours and remains high for 24 hours The half-life of PCT is 24-30 hours. Due to its rapid rise from the onset of bacterial sepsis, it is considered a better marker for early diagnosis of neonatal sepsis compared to CRP. Over 2-2.5 ng/ml after postnatal 72 hours should suggest infection |

SELAIN KULTUR DARAH....

- ✓ Urine for microbiological investigation, ideally by suprapubic aspirate (SPA); if this is not possible then catheter or clean catch is appropriate
- ✓ Tracheal aspirates obtained immediately after intubation. In infants who has
 intubated several days → can only be colonization
- ✓ Gram stains from gastric aspirates, cultures from axilla, groin and external ears →
 limited value, most likely colonization, except for MRSA screening

DIAGNOSIS NEONATAL SEPSIS KULTUR DARAH

Culture proven sepsis

- The isolation of pathogenic bacteria from a blood culture is the gold standard to confirm the diagnosis of neonatal sepsis
- A positive blood culture is diagnostic of sepsis when a bacterial pathogen is isolated

Probable sepsis

- Neonate has a clinical course that is concerning for sepsis
- But a pathogen may not be isolated in culture
- Composite of observational assessment and serial laboratory testing is typically used to make a diagnosis of probable sepsis


Infection unlikely

Infants with mild and/or transient symptoms

(ex; fever alone or other symptoms that quickly resolve) who remain well appearing with normal laboratory values and negative cultures at 48 hours are unlikely to have sepsis.

Armsby C. Official reprint from UpToDate. www.uptodate.com ©2017 UpToDate ® Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants. 2017;1–23.

KAPAN MULAI ANTIBIOTIKA?



PEMAKAIAN ANTIBIOTIKA EMPIRIK

- Try to diagnose the site of infection, do the best educate guess!
- Collect maximized microbiological work up and use the best/fastest methodologies for microbiological diagnosis
- Assess severity
- 4. Assess MDR pathogen's risk factors
- 5. Decide about the need of combination therapy
- 6. Use PK/PD concepts such as prolonged or continuous infusion, with TDM whenever possible
- 7. Use ASP, based on local specificities and data
- 8. Maintain daily assessment of clinical and supporting exam
- Promote source control, whenever needed
- 10. Do not forget non antibiotic adjuvant therapy, whenever indicated

ANTIBIOTICS MANAGEMENT FOR LATE-ONSET NEONATAL SEPSIS

- Empiric treatment with antibiotics should be started as soon as sepsis is clinically suspected, even without confirmatory lab data.
- In general, antimicrobial resistance patterns of common bacteria in the neonatal intensive care
 unit should guide antibiotics 'initial choice'.
- With LOS, nosocomial coverage should be provided for the hospital-acquired pathogens such as coagulase-negative Staphylococcus, S. aureus, and Pseudomonas species

Bacterial pathogens in neonatal sepsis and focal neonatal infections

| | Common pathogens | Some less common pathogens |
|--|---|---|
| Late Onset | | |
| Term and late preterm infants (GA ≥ 34 weeks) | GBS E. coli Additional pathogens seen in the NICU setting- S. aureus, CoNS | Enterobacter, Listeria, Klebsiella, N. meningitidis, other enteric and non enteric gram negative bacilli, Salmonella. pneumoniae, Viridans streptococci Additional pathogens seen in the NICU setting- Citrobacter, Enterococcus, Pseudomonas, Serratia |
| Preterm infants (GA <34 weeks) | - CoNS - S. aureus - GBS - E. coli | Citrobacter, Enterobacter, Enterococcus, Listeria, Klebsiella, other enteric and non-enteric gram negative bacilli, Pseudomonas, Serratia, , Viridans streptococci, Salmonella |

Bacterial pathogens in neonatal sepsis and focal neonatal infections

| | Common pathogens | Some less common pathogens |
|---|---|--|
| Pathogens based on source of infection | | |
| Meningitis | - GBS - E. coli - Other enteric gram negative bacilli | - CoNS, Enterococcus, Listeria, N. meningitidis, non- typeable H. Influenza, S. aureus, S. pneumoniae, other streptococci (groups A. C, or G, and Viridans streptococci) |
| Pneumonia | - GBS | - C. trachomatis, Citrobacter, Enterobacter, Group A Streptococcus, Klebsiella, Pseudomonas, S. aureus, S. pneumoniae, Serratia |
| Urinary Tract Infection | - E. coli | - Citrobacter, Enterobacter, Enterococcus, Klebsiella, Proteus - Additional pathogens seen in the NICU setting- CoNS, S. aureus |
| Skin and soft tissue infection | - S. aureus - GBS - Group A Streptococcus | |
| Vascular catheter- associated infection | - S. aureus - CoNS - Gram negative - Enterococcus | |
| Intestinal source/ NEC | E. coli Klebsiella Other enteric gram negative bacilli Clostridium spp. Anaerobes (eg. Bacteroides) | |

Suggested antimicrobial regimens in the management of neonatal sepsis in term and late preterm infants

| | Antibiotic regimen |
|---|---|
| Empiric therapy | |
| Late onset (\geq 7 days): Admitted from the community | - Ampicillin AND gentamicin |
| Late onset (≥ 7 days): Hospitalized since birth | |
| Special circumstances: | |
| - Suspected meningitis- early onset | - Ampicillin AND gentamicin |
| - Suspected meningitis – late onset, admitted from the community | - Ampicillin, gentamicin AND cefotaxime |
| - Suspected meningitis – late onset, hospitalized since birth | - Gentamicin, vancomycin AND cefotaxime |
| - Suspected pneumonia | Ampicillin AND gentamicin Alternatives: Ampicillin AND cefotaxime/ Vancomycin AND cefotaxime/Vancomycin AND gentamicin |
| - Suspected infection of soft tissue, skin joints, or bones(S. aureus is a likely pathogen) | - Vancomycin or vancomycin AND nafcillin |
| - Suspected intravascular catheter-related infection | - Vancomycin AND gentamycin |
| - Suspected infection due to organisms found in the GIT (eg. Anaerobic bacteria) | Ampicillin, gentamicin AND clindamycin Alternatives: Ampicillin, gentamicin, AND metronidazole / Piperacillin- tazobactam AND gentamicin |

ANTIBIOTICS MANAGEMENT FOR LATE-ONSET NEONATAL SEPSIS

- Review clinical progress and microbiology results at 36 hours (48 hours for late onset sepsis).
 - If cultures negative consider stopping therapy.
 - Continue therapy if cultures positive or sepsis very likely.
- Add <u>metronidazole</u> if suspicion of **anaerobic infection** (e.g. intra-abdominal sepsis, NEC). If abdominal infection/NEC beyond 5 days use amoxicillin in preference to flucloxacillin
- Consider <u>vancomycin</u> for coagulase negative Staphylococcal sepsis, especially if infant unwell or central line infection with line staying in.
- Add <u>cefotaxime</u> if neonatal meningitis. Consider adding cefotaxime early if neonate has a ventricular reservoir or shunt and after reservoir is tapped by neurosurgical team for a CSF sample.
- Consider cefuroxime or piptazobactam for ventilator-associated pneumonia.

Suggested antimicrobial regimens in the management of neonatal sepsis in term and late preterm infants

| | Antibiotic regimen |
|--|--|
| Pathogen specific therapy | |
| Group B Streptococcus | - Penicillin G |
| E. coli: Ampicillin- sensitive | - Ampicillin |
| E. coli: Ampicillin- resistant | - Cefotaxime - Alternative: Meropenem |
| Multidrug- resistant gram negative bacilli (including ESBL- producing organisms) | - Meropenem |
| Listeria monocytogenes | - Ampicillin AND Gentamicin |
| Methicillin- susceptible, S. aureus (MRSA) | - Nafcillin OR cefazolin |
| Methicillin- resistant, S. aureus (MRSA) | - Vancomycin |
| Coagulase- negative staphylococci | - Vancomycin |

Antibiotics for MDROs

ESBL Enterobactericae: E. coli, K. pneumoniae

Carbapenem, Pip-Taz

AmpC: Aeromonas sp., Citrobacter sp., Enterobacter sp., Morganella morganii, Serratia marascens; Yersinia enterocolitica; Pseudomonas aeruginosa

Cefepime, Carbapenem

MRSA

- BSI: Vancomycin
- Paru: Linezolid, Vancomycin
- Kulit, jaringan lunak: Vancomycin, Teicoplanin

XDR A. baumannii dan Pseudomonas:

Colistin/Polymixin B + Carbapenem +/- Fosfomycin

KPC (Klebseiella pneumoniae carbapenemase)

- Colistin/Polymixin B + Carbapenem
- Tygecycilin + Carbapenem

Duration of treatment

| Infection type | Duration (days) of therapy |
|-------------------------|--|
| Pneumonia | 5-7 |
| Septicaemia | 7-10 |
| Urinary Tract Infection | 7-10 |
| Meningitis | 14-21 (depending on organism isolated) |
| Skin conditions | 5 |
| Conjunctivitis | 5-7 |
| Oral thrush | 7-10 |

https://www.starship.org.nz/guidelines/antibiotics-for-neonatal-sepsis/

KULTUR (-), NEONATUS MASIH TAMPAK SAKIT

- ✓ Do a source control
 - ✓ Remove central line
 - ✓ Surgical
 - ✓ Infection control: change ventilator, etc
- ✓ Search for other alternative diagnosis
- ✓ Do further microbiology work up
- ✓ Cross check if your dose is correct
- ✓ Know the nature of the disease

Differential diagnosis of neonatal sepsis

| Diagnosis | Distinguishing features | Diagnostic tests |
|------------------------------------|--|---|
| Other systemic neonatal infections | * | |
| Viral infections: | | |
| Herpes simplex virus | Mucocutaneous vesicles, CSF pleocytosis, elevated CSF protein, thrombocytopenia, hepatitis | Viral culture; HSV PCR |
| Enteroviruses | Fulminant systemic disease, myocarditis, hepatitis, encephalitis | Viral culture; EV PCR |
| Parechovirus | Encephalitis/meningitis, rash on palms and soles | HPeV PCR (available through CDC) |
| Cytomegalovirus | Thrombocytopenia, periventricular intracranial calcifications, microcephaly, sensorineural hearing loss, chorioretinitis | Viral culture; CMV PCR |
| Influenza viruses | Respiratory symptoms, rhinorrhea, gastrointestinal symptoms | Viral culture; influenza-specific antigen detection or immunofluorescence assay |
| Respiratory syncytial virus | Respiratory symptoms, rhinorrhea, cough, apnea, pneumonia | Viral culture; RSV-specific antigen detection or immunofluorescence assay |
| Spirochetal infections – Syphilis | Skeletal abnormalities (osteochondritis and periostitis), pseudoparalysis, persistent rhinitis, maculopapular rash (particularly on palms and soles or in diaper area) | RPR or VDRL |
| Parasitic infections: | | |
| Congenital malaria | Anemia, splenomegaly, jaundice | Detection of parasitemia on blood smear |
| Toxoplasmosis | Intracranial calcifications (diffuse), hydrocephalus, chorioretinitis, mononuclear CSF pleocytosis, elevated CSF protein | Toxoplasma gondii serology |
| Fungal infection – Candidiasis | Persistent hyperglycemia, thrombocytopenia, multiorgan failure | Isolation of Candida in blood, urine, or CSF culture |

| ioninfectious causes of temperature instability in neonat | es | |
|--|--|--|
| Altered environmental temperature | Transient; no other systemic symptoms; resolves with simple nonpharmacologic measures | |
| Dehydration | Clinical history of poor feeding or fluid losses (eg, vomiting and/or diarrhea) | |
| Neonatal abstinence syndrome | History of maternal drug use; sweating, sneezing, nasal stuffiness, and yawning | Positive drug screening tests |
| CNS insult (eg, anoxia or hemorrhage) | History of perinatal asphyxia; focal neurologic findings or seizures | Abnormal neuroimaging studies |
| Hypothyroidism | Hypotonia, lethargy, hypothermia, large fontanels | Abnormal T4 or TSH level on newborn screen |
| Congenital adrenal hyperplasia | Ambiguous genitalia (females), adrenal insufficiency and salt-wasting (hyponatremia, hyperkalemia, dehydration) | Abnormal 17a-hydroxyprogesterone level on newborn screen |
| ioninfectious causes of respiratory and cardiocirculatory | symptoms in neonates | |
| Transient tachypnea of the newborn | Onset of symptoms within two hours after delivery; symptoms usually resolve within 24 hours | CXR findings include increased lung volumes, mild cardiomegaly, prominent vascular markings, fluid in the interlobar fissures, and pleural effusions |
| Respiratory distress syndrome | Most common in preterm infants; rare in term infants; onset of symptoms within first few hours after delivery, progressively worsens over first 48 hours of life | CXR findings include low lung volume and diffuse reticulogranular ground glass appearance with air bronchograms |
| Meconium aspiration | History of meconium-stained amniotic fluid; respiratory distress occurs immediately after birth | Initial CXR may show streaky, linear densities; as the disease progresses, the lungs may appear hyperinflated with diffuse patchy densities |
| Pneumothorax | Asymmetric chest rise, decreased breath sounds on affected side; hypotension (in cases of tension pneumothorax) | CXR will usually detect symptomatic pneumothoraces |
| Congenital anomalies (including tracheal-esophageal fistula, choanal atresia, and diaphragmatic hemia) | Often occur with other congenital anomalies including VACTERL and CHARGE associations; choanal atresia is characterized by noisy labored breathing while feeding | CDH is often diagnosed by routine antenatal ultrasound screening; postnatal CXR shows hemiation of abdomina contents into hemithorax; TEF is diagnosed with upper gastrointestinal series and/or bronchoscopy |
| Neonatal abstinence syndrome | History of maternal drug use; sweating, sneezing, nasal stuffiness, and yawning | Positive drug screening tests |
| Cardiac arrhythmias (eg, supraventricular tachycardia) | Abrupt onset and termination of rapid heart rate | Abnormal ECG |
| Congenital heart disease | Infants with ductal-dependent lesions may initially lack symptoms then develop cyanosis and rapid clinical deterioration as the PDA closes in the first few days of life | Abnormal hyperoxia test; abnormal echocardiography |

| Noninfectious causes of neurologic symptoms in neonate | 5 | |
|--|--|---|
| Hypoglycemia | Common in infants who are large for gestational age and/or infants of diabetic mothers | Abnormal blood glucose level |
| Hypercalcemia | Increased neuromuscular irritability and seizures; associated with prematurity, maternal diabetes, and perinatal asphyxia | Abnormal serum calcium level |
| Hypermagnesemia | Generalized hypotonia, respiratory depression and apnea; typically results from maternal treatment with magnesium sulfate | Abnormal serum magnesium level |
| CNS insult (eg, anoxía or hemorrhage) | History of perinatal asphyxia; focal neurologic findings or seizures | Abnormal neuroimaging studies |
| Congenital CNS malformations (eg, hydrocephalus) | Abnormal head circumference | Abnormal neuroimaging studies |
| Neonatal abstinence syndrome | History of maternal drug use; sweating, sneezing, nasal stuffiness, and yawning | Positive drug screening tests |
| Inborn errors of metabolism | Otherwise unexplained acid-base disorders, hyperammonemia, hypoglycemia, hematologic abnormalities, liver dysfunction, and renal disease | Positive newborn screen for inborn errors of metabolism |
| Pyridoxine deficiency | Refractory seizures | Abnormal plasma pyridoxal-5-phophate level |

CSF: cerebral spinal fluid; HSV: herpes simplex virus; PCR: polymerase chain reaction; EV: enterovirus; HPeV: human parechovirus; CMV: cytomegalovirus; RSV: respiratory syncytial virus; RPR: rapid plasma reagin; VDRL: venereal disease research laboratory; CNS: central nervous system; T4: thyroxine; TSH: thyrotropin; CXR: chest radiograph; CDH: congenital diaphragmatic hernia; VACTERL: malformations of the vertebrae, anus, cardiac structures, trachea, esophagus, renal system, and limbs; CHARGE: coloboma of the iris or choroid, heart defect, atresia of the choanae, retarded growth and development, genitourinary abnormalities, and ear defects; TEF: tracheoesophageal fistula; ECG: electrocardiogram; PDA: patent ductus arteriosus.

Adapted from: Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the fetus and newborn infant, 7th ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010.



TERIMA KASIH....

